JP2020534840A5 - - Google Patents

Info

Publication number
JP2020534840A5
JP2020534840A5 JP2020517828A JP2020517828A JP2020534840A5 JP 2020534840 A5 JP2020534840 A5 JP 2020534840A5 JP 2020517828 A JP2020517828 A JP 2020517828A JP 2020517828 A JP2020517828 A JP 2020517828A JP 2020534840 A5 JP2020534840 A5 JP 2020534840A5
Authority
JP
Japan
Prior art keywords
glp
derivative
conjugate
group
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020517828A
Other languages
English (en)
Japanese (ja)
Other versions
JP7751381B2 (ja
JP2020534840A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2018/011586 external-priority patent/WO2019066586A1/ko
Publication of JP2020534840A publication Critical patent/JP2020534840A/ja
Priority to JP2023111438A priority Critical patent/JP2023138505A/ja
Publication of JP2020534840A5 publication Critical patent/JP2020534840A5/ja
Application granted granted Critical
Publication of JP7751381B2 publication Critical patent/JP7751381B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020517828A 2017-09-28 2018-09-28 Glp-2誘導体の持続型結合体 Active JP7751381B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023111438A JP2023138505A (ja) 2017-09-28 2023-07-06 Glp-2誘導体の持続型結合体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170126577 2017-09-28
KR10-2017-0126577 2017-09-28
PCT/KR2018/011586 WO2019066586A1 (ko) 2017-09-28 2018-09-28 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023111438A Division JP2023138505A (ja) 2017-09-28 2023-07-06 Glp-2誘導体の持続型結合体

Publications (3)

Publication Number Publication Date
JP2020534840A JP2020534840A (ja) 2020-12-03
JP2020534840A5 true JP2020534840A5 (cg-RX-API-DMAC7.html) 2023-07-24
JP7751381B2 JP7751381B2 (ja) 2025-10-08

Family

ID=65902619

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020517828A Active JP7751381B2 (ja) 2017-09-28 2018-09-28 Glp-2誘導体の持続型結合体
JP2023111438A Pending JP2023138505A (ja) 2017-09-28 2023-07-06 Glp-2誘導体の持続型結合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023111438A Pending JP2023138505A (ja) 2017-09-28 2023-07-06 Glp-2誘導体の持続型結合体

Country Status (22)

Country Link
US (3) US11530249B2 (cg-RX-API-DMAC7.html)
EP (1) EP3689898B1 (cg-RX-API-DMAC7.html)
JP (2) JP7751381B2 (cg-RX-API-DMAC7.html)
KR (2) KR102681143B1 (cg-RX-API-DMAC7.html)
CN (1) CN111433221B (cg-RX-API-DMAC7.html)
AR (1) AR113258A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018339210B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020006189A2 (cg-RX-API-DMAC7.html)
CA (1) CA3084326A1 (cg-RX-API-DMAC7.html)
DK (1) DK3689898T3 (cg-RX-API-DMAC7.html)
EA (1) EA202090571A1 (cg-RX-API-DMAC7.html)
ES (1) ES3075688T3 (cg-RX-API-DMAC7.html)
FI (1) FI3689898T3 (cg-RX-API-DMAC7.html)
IL (1) IL273528B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004453A (cg-RX-API-DMAC7.html)
PH (1) PH12020550105A1 (cg-RX-API-DMAC7.html)
PT (1) PT3689898T (cg-RX-API-DMAC7.html)
SA (1) SA520411644B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202002563WA (cg-RX-API-DMAC7.html)
TW (2) TWI794897B (cg-RX-API-DMAC7.html)
WO (1) WO2019066586A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202001888B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
EP4082561A4 (en) * 2019-12-24 2024-02-07 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating metabolic bone diseases, comprising glp-2 or conjugate thereof
US20230110689A1 (en) 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
CN115697375A (zh) * 2020-04-03 2023-02-03 韩美药品株式会社 预防或治疗放疗、化疗或其组合引发的粘膜炎的包含glp-2衍生物或其长效缀合物的药物组合物
IL298298A (en) 2020-05-22 2023-01-01 Hanmi Pharm Ind Co Ltd A liquid formulation of a long-acting conjugate of glp–2
CA3182260A1 (en) 2020-06-09 2021-12-16 Gleb Feldman Manufacture, formulation and dosing of apraglutide
CA3201916A1 (en) * 2020-12-24 2022-06-30 Hanmi Pharm. Co., Ltd. Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome
US20250276044A1 (en) * 2022-04-18 2025-09-04 Hanmi Pharm. Co., Ltd. COMBINATION THERAPY COMPRISING GLP-2, AND INSULINOTROPIC PEPTIDE, TNFa INHIBITOR, OR BOTH FOR PREVENTING OR TREATING BOWEL DISEASE
JP2026501948A (ja) 2022-12-23 2026-01-19 ハンミ ファーマシューティカル カンパニー リミテッド Glp-2誘導体又はその持続型結合体を含む移植片対宿主病の予防又は治療用薬学的組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
DK1360202T3 (da) * 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
US20090238838A1 (en) * 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
ES2347902T3 (es) * 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
DE602006020123D1 (de) * 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
KR101746686B1 (ko) * 2010-10-26 2017-06-15 한미사이언스 주식회사 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―2(glp―2)약물 결합체
ES2687651T3 (es) * 2011-09-12 2018-10-26 Amunix Operating Inc. Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체

Similar Documents

Publication Publication Date Title
IL273528B2 (en) Long-acting conjugates of glp-2 derivatives
JP2015503554A5 (cg-RX-API-DMAC7.html)
RU2009129953A (ru) Инсулинотропный комплекс, в котором использован фрагмент иммуноглобулина
Lutz Polymerization of oligo (ethylene glycol)(meth) acrylates: Toward new generations of smart biocompatible materials
JP4560210B2 (ja) 薬物複合体
JP5909755B2 (ja) 非血液凝固タンパク質の糖ポリシアル酸化
US20170028075A1 (en) Injectable dendrimer hydrogel nanoparticles
CN102985462B (zh) 支链异聚乙二醇和中间体
JP2003535591A5 (cg-RX-API-DMAC7.html)
JP2020534030A5 (cg-RX-API-DMAC7.html)
WO1997046261A1 (fr) Procede de fabrication de complexes medicamenteux
JP2018510863A5 (cg-RX-API-DMAC7.html)
WO2004046222A1 (ja) 修飾された生体関連物質、その製造方法および中間体
EP2065392A3 (en) Fusion antigen uses as vaccine
JP6208269B2 (ja) 非血液凝固タンパク質の糖ポリシアル酸化
JP2002506087A (ja) 近位の反応性基を持つポリ(エチレングリコール)誘導体
Seelbach et al. Injectable hyaluronan hydrogels with peptide‐binding dendrimers modulate the controlled release of BMP‐2 and TGF‐β1
JP2002516284A5 (cg-RX-API-DMAC7.html)
Hiki et al. Versatile and selective synthesis of “click chemistry” compatible heterobifunctional poly (ethylene glycol) s possessing azide and alkyne functionalities
RU2018127330A (ru) Композиция, включающая агонист рецептора glp-1 и агонист глюкагонового рецептора, и ее применение
JP2015514086A5 (cg-RX-API-DMAC7.html)
JP5281358B2 (ja) 高分子、経上皮吸収促進剤、及び医薬用製剤
KR101761092B1 (ko) 췌도 세포 이식용 조성물
Joshi et al. Synthesis of potent inhibitors of anthrax toxin based on poly-L-glutamic acid
US7863408B2 (en) Body fluid compatible and biocompatible resin